# Senseera

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/senseera

- Industry: Medical Devices & Equipment
- Headquarters: Jerusalem, Israel
- Website: www.senseerahealth.com
- Total disclosed funding: $7.1M
- Latest round: Seed (Jan 7, 2025)
- Investors on record: 3

## About

Founded in 2020 and based in Jerusalem, Israel, Senseera Ltd. operates as a developer of a biomarker discovery platform. In January 2025, Senseera Ltd. raised USD 7.1 million in seed funding led by investor Lightspeed Venture Partners, with participation from other investors i-Next Ventures and Lowy Medical Research Institute. The firm as of Jnauary 2025, is led by its CEO, Ronen Sadeh.

Senseera’s platform specializes in detecting and analyzing biomarkers from blood samples for non-invasive diagnostics and personalized medicine. Its core technology, cfChIP-seq, profiles chromatin interactions and epigenetic modifications in circulating biomolecules, aiding in the understanding of disease mechanisms and drug development. Additionally, Senseera offers the GEM BIOMARKERS™ platform, which focuses on liquid biopsy applications for non-invasive disease detection, particularly in cancer. Serving pharmaceutical companies and research institutions, Senseera primarily operates in North American and European markets.

Senseera generates revenue through business-to-business transactions primarily involving pharmaceutical and biotechnology firms seeking solutions for drug development and disease monitoring.

The company plans to utilize the January 2025 funding to advance the development of its liquid biopsy platform, Gem Biomakers.

## Funding rounds

- Seed, Jan 7, 2025, $7.1M — Lightspeed Venture Partners, i-Next Ventures, Lowy Medical Research Institute

## Investors

- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Seed
- i-Next Ventures (https://capitalatlas.ai/funds/i-next-ventures) — Seed
- Lowy Medical Research Institute — Seed